Infectious complications of the respiratory tract and lungs in patients with post-COVID syndrome

DOI: https://doi.org/10.32902/2663-0338-2022-4-20-29

Abstract

BACKGROUND. The mechanism of development of post-COVID syndrome is not fully understood. Long-term retention of complaints in patients is associated with long-term persistence of the virus, hyperinflammatory response of the body, as well as with the peculiarities of the patient’s cellular and humoral immunity. Secondary infectious complications in the post-COVID period are due not only to the ability of the SARS-CoV-2 virus to damage erythrocytes and attack the red bone marrow in the acute phase of the disease. It has been proven that the SARS-CoV-2 virus leads to the disappearance of white pulp cells in the spleen, the tissue where cells of the immune response, in particular T- and B-lymphocytes responsible for infectious immunity, mature.

OBJECTIVE. To investigate the frequency of secondary infectious complications of the respiratory tract and lungs in patients with post-COVID syndrome who underwent inpatient treatment.

MATERIALS AND METHODS. Clinical, laboratory and radiological data of 90 patients with post-COVID syndrome who were undergoing inpatient treatment in the clinical departments of the SI “National institute of phthisiology and pulmonology named after F.G. Yanovsky of the NAMS of Ukraine”. The diagnosis of coronavirus disease (COVID-19) was established in accordance with the current national protocol for the treatment. Computed tomography (CT) of the chest organs was performed on the Aquilion TSX-101A scanner (Toshiba, Japan).

RESULTS AND DISCUSSION. Complications of COVID-19 were determined according to the clinical and functional, laboratory examination and CT scan of the chest. Some patients had two or more complications at the same time. Patients with post-COVID syndrome were most often hospitalized for progression or slight positive dynamics of the pathological process of the respiratory tract and lungs, disappearing lung syndrome, fibrotic changes in the lungs, exacerbation of bronchoobstructive lung diseases and infectious complications. The latter were observed most often – in 53,3 % of patients. Fungal and bacterial complications occurred secondarily, mainly in patients with disappearing lung syndrome, in places where cystlike cavities were formed. The most common concomitant diseases in patients with post-COVID syndrome were cardiovascular diseases and diabetes.

CONCLUSIONS. The proportion of infectious complications of the respiratory tract and lungs in patients with post-COVID syndrome, who are indicated for inpatient treatment in the pulmonology department, is 53.3 %. The most frequent causes of infectious complications of the respiratory tract and lungs in patients with post-COVID syndrome are the reactivation of the Epstein – Barr virus infection – in 30.0 %, which in 2.2 % of patients is combined with the reactivation of the hepatitis C virus, and bacterial infections – in 15.6 %. Aspergillosis and mucormycosis occur in 1.1 and 3.3 % of patients respectively.

Keywords: COVID-19, SARS-CoV-2, diagnostics, post-COVID syndrome, infectious complications, computed tomography

References

Duda O.K., Manzhelieieva I.V., Veha A.R. Postkovidnyi syndrom – nova aktualna problema suchasnoi medytsyny. Infektsiini khvoroby. 2020; 4 (102): 5-11. doi: 10.11603/1681-2727.2020.4.11890.

Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2020.

NICE guideline. COVID-19 rapid guideline: managing the long-term effects of COVID-19. Available at: www.nice.org.uk/guidance/NG188.

Carfì A., Bernabei R., Landi F., et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020; 324 (6): 603-605.

Garg P., Arora U., Kumar A., Wig N. The “post-COVID” syndrome: how deep is the damage? Journal of Medical Virology. 2020; 93 (2).

Komaroff A. The tragedy of the post-COVID “long haulers”. Harvard Health Letter. 2020.

Pertseva T.O., Bielosludtseva K.O., Krykhtina M.A. Prohnozuvannia trombotychnykh uskladnen u khvorykh na nehospitalnu pnevmoniiu za danymy bahatovymirnoho analizu tiazhkosti, systemnoho zapalennia, stanu endotelialnoi funktsii ta hemostazu. Infusion & Chemotherapy. 2021; 3: 12-17. doi: 10.32902/2663-0338-2021-3-12-17.

Lynnyk M.I., Ignatieva V.I., Gumeniuk G.L., Sviatnenko V.A. ta in. Diahnostyka uskladnenoho perebihu nehospitalnoi pnevmonii virusnoi etiolohii (COVID-19) iz vykorystanniam kompiuternoi tomohrafii orhaniv hrudnoi klitky. Infusion & Chemotherapy. 2021; 2: 11-18. doi: 10.32902/2663-0338-2021-2-11-18.

Linnik N.I., Gumeniuk N.I., Liskina I.V., Gumeniuk G.L., Ignatieva V.I., Tarasenko E.R. Osobennosti oslozhnennogo techeniya negospitalnoy virusnoy COVID-19 pnevmonii. Georgial Medical News. 2021; 6 (315): 129-134.

Ripa M., Galli L., Poli A., Oltolini C., Spagnuolo V., Mastrangelo A., et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin. Microbiol. Infect. 2021; 27 (3): 451-457. doi: 10.1016/j.cmi.2020.10.021.

Zhang H., Zhang Y., Wu J., Li Y., Zhou X., Li X., et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients. Emerg. Microbes Infect. 2020; 9 (1): 1958-1964. doi: 10.1080/22221751.2020.1812437.

Lynnyk M.I., Gumeniuk M.I., Liskina V.I., Ignatieva V.I. ta in. Diahnostyka urazhen parenkhimatoznykh orhaniv pry COVID-19 iz zastosuvanniam tsyfrovoi prohramnoi obrobky zobrazhen kompiuternoi tomohrafii. Infusion & Chemotherapy. 2021; 4: 16-24. doi: 10.32902/2663-0338-2021-4-16-24.

Taramasso L., Magnasco L., Portunato F., Briano F., Vena A., Giacobbe D.R., et al. Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care. Eur. J. Intern. Med. 2021; 94: 39-44. doi: 10.1016/j.ejim.2021.08.020.

Casalini G., Giacomelli A., Ridolfo A., Gervasoni C., Antinori S. Invasive fungal infections complicating COVID-19: a narrative review. J. Fungi (Basel). 2021; 7 (11): 921. doi: 10.3390/jof7110921.

Ghanem H., Sivasubramanian G. Cryptococcus neoformans meningoencephalitis in an immunocompetent patient after COVID-19 infection. Case Rep. Infect. Dis. 2021; 2021: 5597473. doi: 10.1155/2021/5597473.

Varshney V.K., Swami A., Thirunavukkarasu B., et al. Synchronous small bowel gangrene with pyelonephritis secondary to mucormycosis: a disastrous complication of COVID-19 pandemic. Cureus. 2021; 13 (6): e15911. doi: 10.7759/cureus.15911.

Makhdoomi R., Malik N., Charan J., et al. Spinal aspergillosis: a rare complication of COVID-19 infection. Egypt J. Neurosurg. 2022; 37 (6). doi: 10.1186/s41984-021-00140-y.

Meng M., Zhang S., Dong X., Sun W., Deng Y., Li W., et al. COVID-19 associated EBV reactivation and effects of ganciclovir treatment. Immun. Inflamm. Dis. 2022; 10 (4): e597. doi: 10.1002/iid3.597.

Ignatieva V.I. Reaktyvatsiia virusnoi infektsii Epshteina – Barr yak odna z prychyn hiperdiahnostyky bronkhialnoi astmy. Astma ta alerhiia. 2020; 1: 54-62. doi: 10.31655/2307-3373-2020-1-54-62.

Peluso M.J., Deveau T.M., Munter S.E., Ryder D., Buck A., Beck-Engeser G., et al. Impact of pre-existing chronic viral infection and reactivation on the development of long COVID. medRxiv [Preprint]. 2022: 2022.06.21.22276660. doi: 10.1101/2022.06.21.22276660.

Aldhaleei W.A., Alnuaimi A., Bhagavathula A.S. COVID-19 induced hepatitis B virus reactivation: a novel case from the United Arab Emirates. Cureus. 2020 Jun 15; 12 (6): e8645. doi: 10.7759/cureus.8645.

Desai H.D., Sharma K., Patoliya J.V., Ahadov E., Patel N.N. A rare case of varicella-zoster virus reactivation following recovery from COVID-19. Cureus. 2021 Jan 1; 13 (1): e12423. doi: 10.7759/cureus.12423.

Drago F., Ciccarese G., Rebora A., Parodi A. Human herpesvirus-6, -7, and Epstein – Barr virus reactivation in pityriasis rosea during COVID-19. J. Med. Virol. 2021 Apr; 93 (4): 1850-1851. doi: 10.1002/jmv.26549.

Williamson E., Walker A., Bhaskaran K., et al. Factors associated with COVID-19 – related death using OpenSAFELY. Nature. 2020; 584: 430-436.

Yang J., Zheng Y., Gou X., et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and metaanalysis. Int. J. Infect. Dis. 2020; 94: 91-95. doi: 10.1016/j.ijid.2020.03.017.

Published
2022-12-28
How to Cite
YakovenkoО., LynnykМ., ІgnatievaV., Gumeniuk, G., Opimakh, S., Polianska, M., Zvol, I., & Moskalenko, S. (2022). Infectious complications of the respiratory tract and lungs in patients with post-COVID syndrome. Infusion & Chemotherapy, (4), 20-29. https://doi.org/10.32902/2663-0338-2022-4-20-29
Issue
No. 4 (2022): INFUSION & CHEMOTHERAPY
Section
ORIGINAL STUDIES

Author Biographies

О.К. Yakovenko, ME “Volyn Regional Clinical Hospital”, Volyn Regional Council, Lutsk, Ukraine

Yakovenko Oleg Kostiantynovych
Head of pulmonology department
PhD.
21, Hrushevskogo ave., Lutsk, 43005, Ukraine.

М.І. Lynnyk, SI “National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine

Lynnyk Mykola Ivanovych
Head of epidemiology and organizational problems of phthisiology department
MD.
10, M. Amosova st., Kyiv, 03038, Ukraine.
Phone/fax: +38 (096) 5 222 111.
E-mail: nicklinnik1957@gmail.com

V.І. Іgnatieva, SI “National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine

Ignatieva Victoria Igorivna
Senior researcher, Department of diagnostics, therapy and clinical pharmacology of lung diseases
PhD.
10, M. Amosova st., Kyiv, 03038, Ukraine.

G.L. Gumeniuk, National University of Healthcare of Ukraine named after P.L. Shupyk, Kyiv, Ukraine

Gumeniuk Galyna Lvivna
Professor of phthisiology and pulmonology department
MD.
9, Dorohozhytska st., Kyiv, 04112, Ukraine.

S.G. Opimakh, SI “National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine

Opimakh Svitlana Genrikhivna
Senior researcher, Department of diagnostics, therapy and clinical pharmacology of lung diseases
PhD.
10, M. Amosova st., Kyiv, 03038, Ukraine.

M.A. Polianska, SI “National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine

Polianska Maryna Oleksandrivna
Head of the Department of diagnostics, therapy and clinical pharmacology of lung diseases
PhD.
10, M. Amosova st., Kyiv, 03038, Ukraine.

I.V. Zvol, SI “National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine

Zvol Іnna Volodymyrivna
Senior researcher, Department of diagnostics, therapy and clinical pharmacology of lung diseases
PhD.
10, M. Amosova st., Kyiv, 03038, Ukraine.

S.M. Moskalenko, SI “National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine

Мoskalenko Svitlana Mykhailivna
Senior researcher, Department of diagnostics, therapy and clinical pharmacology of lung diseases,
PhD.
10, M. Amosova st., Kyiv, 03038, Ukraine.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)